Document is current
Any future updates will be listed below
-
Authors
Weiss, Anna
Colugnati, Fernando
Mitchell, Melissa
Li, Yue
Marin, Chelsea
Gergelis, Kimberly R.
O’Sullivan, Ciara C.
Boughey, Judy C.
- License Information
-
More Information
Article History
First Online: 8 August 2024
Disclosure
: Anna Weiss reports paid advisory board participation for Abbvie, Merck, and Myriad, and has received honoraria from OncLive (MJH Lifesciences), Empire State Hematology & Oncology Society, and the Society of Breast Imaging. Melissa Mitchell receives funding from ARTIDIS, and has received honoraria from PER and DAVA Oncology. Kimberly R. Gergelis has received honoraria from OncLive and the Empire State Hematology & Oncology Society. Ciara C. O’Sullivan has received research funding, paid to the Mayo Clinic, from Lilly, Seagen Inc., Eisai, Bavarian Nordic, Minnemarita Therapeutics, nFerence, AstraZeneca and Biovica, and has received honoraria from OncLive, Medscape, AstraZeneca and Seagen Inc. Judy C. Boughey receives funding, paid to her institution, from Eli Lilly and SymBioSis, and sits on the Data Safety Monitoring Committee of CairnsSurgical. She has also received honoraria from PER, PeerView, OncLive, and Up-To-Date. Fernando Colugnati, Yue Li, and Chelsea Marin have no conflicts of interest to declare that may be relevant to the contents of this work.
